Vivacta Bio and Grit Bio Announce FDA Orphan Drug Designation for In Vivo CAR-T Therapy GT801 in Autoimmune Hemolytic Anemia

RegulatoryGT801Positive

AI Analysis

Summary

Vivacta Bio, a spinout from Grit Bio's in vivo CAR-T platform, announced the FDA granted Orphan Drug Designation to GT801 for autoimmune hemolytic anemia. The article excerpt provides no clinical data or financial details.

Outcome Details

FDA granted Orphan Drug Designation to in vivo CAR-T therapy GT801 for autoimmune hemolytic anemia.

Importance:5/10

Sentiment:

0.50

orphan drug designationin vivo CAR-Tautoimmune hemolytic anemiaFDAregulatorycell therapyChina biotech

Read the original article

Published by PR Newswire Biotech on October 17, 2026 12:00 PM

Read Original